Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Gyan

Showing results (111-120 of 174) with videos related to

Pageof 18
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|September 9, 2021
Infection in Patients with Suspected Thrombotic Microangiopathy Based on Clinical PresentationBenjamin Thoreau, Florent von Tokarski, Adeline Bauvois, et al.
Bone Marrow Transplantation|March 4, 2021
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trialBenoit Tessoulin, David Chiron, Catherine Thieblemont, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 14, 2019
Etiology and Outcomes of Thrombotic MicroangiopathiesGuillaume Bayer, Florent von Tokarski, Benjamin Thoreau, et al.
Blood Advances|April 17, 2023
Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA groupYassine Al Tabaa, Rene Oliver Casasnovas, Clio Baillet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2011
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participantsJudith Trotman, Marion Fournier, Thierry Lamy, et al.
Haematologica|March 12, 2010
Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS groupRémy Gressin, Sylvie Caulet-Maugendre, Eric Deconinck, et al.
British Journal of Haematology|April 26, 2025
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA groupCharles Herbaux, Emmanuel Bachy, Reda Bouabdallah, et al.
Blood|October 29, 2008
High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 yearsEmmanuel Gyan, Charles Foussard, Philippe Bertrand, et al.
Hematological Oncology|May 31, 2020
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA groupYannick Le Bris, Florence Magrangeas, Anne Moreau, et al.
Blood|December 14, 2011
Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromesEmilie Frisan, Julie Vandekerckhove, Aurélie de Thonel, et al.
Pageof 18

Showing results (111-120 of 174) with videos related to

Sort By:
Pageof 18
Clinical Journal of the American Society of Nephrology : CJASN|September 9, 2021
Infection in Patients with Suspected Thrombotic Microangiopathy Based on Clinical PresentationBenjamin Thoreau, Florent von Tokarski, Adeline Bauvois, et al.
Bone Marrow Transplantation|March 4, 2021
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trialBenoit Tessoulin, David Chiron, Catherine Thieblemont, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 14, 2019
Etiology and Outcomes of Thrombotic MicroangiopathiesGuillaume Bayer, Florent von Tokarski, Benjamin Thoreau, et al.
Blood Advances|April 17, 2023
Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA groupYassine Al Tabaa, Rene Oliver Casasnovas, Clio Baillet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2011
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participantsJudith Trotman, Marion Fournier, Thierry Lamy, et al.
Haematologica|March 12, 2010
Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS groupRémy Gressin, Sylvie Caulet-Maugendre, Eric Deconinck, et al.
British Journal of Haematology|April 26, 2025
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA groupCharles Herbaux, Emmanuel Bachy, Reda Bouabdallah, et al.
Blood|October 29, 2008
High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 yearsEmmanuel Gyan, Charles Foussard, Philippe Bertrand, et al.
Hematological Oncology|May 31, 2020
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA groupYannick Le Bris, Florence Magrangeas, Anne Moreau, et al.
Blood|December 14, 2011
Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromesEmilie Frisan, Julie Vandekerckhove, Aurélie de Thonel, et al.
Pageof 18